Lifecore Biomedical (LFCR) AI Stock Analysis

• Market Cap: $245.03M
• Dividend Yield: N/A
• Average Volume (3M): 204.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 0.47%
• EPS Growth: -430.88%
• Country: US
• Employees: 524
• Sector: N/A
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 37,466,350
• 10 Day Avg. Volume: 178,832
• 30 Day Avg. Volume: 204,257
• PEG Ratio: 0.01
• Price to Book (P/B): 175.14
• Price to Sales (P/S): 1.82
• P/FCF Ratio: -17.18
• Enterprise Value/Market Cap: 1.48
• Enterprise Value/Revenue: 2.69
• Enterprise Value/Gross Profit: 8.52
• Enterprise Value/Ebitda: -51.63
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $6.50 ▼(-15.69% Downside)
• Action: Reiterated Date: 01/17/26
• Date: Action: Reiterated 01/17/26

The score is primarily held down by weak financial performance (ongoing losses, high leverage, and challenged cash flow). Technicals provide some support with the stock trading above key moving averages and neutral momentum, while valuation remains constrained by negative earnings (negative P/E). A recent incentive-plan change is a minor positive but not a fundamental offset to the financial risks.

Lifecore Biomedical Business Overview & Revenue Model

Company Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

How the Company Makes Money

Lifecore Biomedical generates revenue through multiple key streams. The primary source of income comes from the sale of its proprietary hyaluronic acid products, which are utilized in a range of medical procedures, including joint injections and surgical applications. Additionally, the company earns revenue through contract manufacturing services, where it partners with other medical firms to produce specialized products on a contractual basis. Significant partnerships with healthcare providers and medical device companies enhance Lifecore's market presence and contribute to its earnings by expanding its distribution channels and product offerings. Furthermore, the company's commitment to innovation and development of new medical technologies positions it to capture emerging market opportunities, thereby fostering growth in its revenue.

Lifecore Biomedical Financial Statement Overview

Summary

Financials are weak overall: modest revenue growth (4.97% TTM) is outweighed by persistent profitability issues (negative net profit and EBIT margins) and a highly levered balance sheet (debt-to-equity 2.76, low equity ratio, negative ROE). Cash flow trends are also challenged, with negative free cash flow growth.

Income Statement

Lifecore Biomedical shows a modest revenue growth rate of 4.97% TTM, indicating some positive momentum. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively stable at 31.27%, but overall profitability remains a concern due to consistent net losses.

Balance Sheet

The balance sheet reflects high leverage with a debt-to-equity ratio of 2.76, indicating significant reliance on debt financing. The negative return on equity suggests that the company is not generating sufficient returns on shareholders' investments. The equity ratio is low, highlighting potential financial instability.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow growth and a low operating cash flow to net income ratio. Despite these issues, the free cash flow to net income ratio is relatively high, suggesting some efficiency in converting net income to cash flow. However, overall cash flow management needs improvement.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Lifecore Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Negative. The current price of 7.71 is above the 20-day moving average (MA) of 7.07, above the 50-day MA of 7.62, and above the 200-day MA of 7.48, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 26.94 is Positive, neither overbought nor oversold. The STOCH value of 21.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFCR.

Lifecore Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
IRWD	61 Neutral	$549.51M	22.76	-8.22%	―	-10.42%	―
BIOA	59 Neutral	$781.61M	-2.61	-25.09%	―	―	-1.89%
DERM	57 Neutral	$240.11M	-19.19	-39.94%	―	2.82%	60.26%
CPIX	52 Neutral	$45.47M	-20.99	-13.08%	―	12.21%	69.91%
LFCR	45 Neutral	$245.03M	-6.89	―	―	0.47%	-430.88%

Lifecore Biomedical Corporate Events

Lifecore Sets 2026 Annual Meeting, Proposal Deadlines

On August 1, 2025, Lifecore Biomedical’s board approved a shift in its fiscal year from one ending on the last Sunday in May to a calendar-year basis ending December 31, effective for the fiscal period from May 26, 2025 to December 31, 2025, aligning its SEC reporting and annual meeting schedule with calendar-year reporting norms. Reflecting this change, on March 5, 2026 the board set June 4, 2026 as the date of the 2026 annual shareholders’ meeting, and moved the deadline for qualified shareholder proposals and director nominations to March 16, 2026, with submissions required to meet SEC rules, the company’s bylaws, and Delaware law.

The most recent analyst rating on (LFCR) stock is a Sell with a $6.50 price target. To see the full list of analyst forecasts on Lifecore Biomedical stock, see the LFCR Stock Forecast page.

Lifecore Biomedical Adopts New Performance-Based Incentive Bonus Plan

On January 14, 2026, Lifecore Biomedical, Inc.’s Compensation Committee approved and adopted a new Incentive Bonus Plan, effective the same date, to govern bonus awards granted from that point forward. The plan establishes a structured, performance-based cash bonus framework for executive officers and selected employees, with payouts tied to financial and other performance targets and with the Compensation Committee retaining broad discretion over participant selection, performance periods, target weighting, award sizing, and adjustments for unusual corporate events such as acquisitions or divestitures, underscoring a stronger linkage between employee compensation and the company’s strategic and financial performance.

The most recent analyst rating on (LFCR) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Lifecore Biomedical stock, see the LFCR Stock Forecast page.